ClinicalTrials.gg
RecruitingNCT07418034SAVEDUpdated Nov 6, 2026

A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)

A Phase 2 interventional study of Dose de-escalation to contralateral neck. and Dose de-escalation to gross disease to contralateral neck in Head and Neck Cancer, Head and Neck Squamous Cell Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by University of Maryland, Baltimore. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 6, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,317 studies in Head and Neck Neoplasms with a site in United States — 187 open to participants now, 283 under way, 15 of them phase 3. Head and Neck Neoplasms · United States.

Planned enrollment
179th of 1,073
132 · median 36
Started
2026
with 57 others
Phase 2
354 of 1,317
42 open now
Primary completion
2031-05
later than 266 of 282 live
Registered
1,270th of 1,317
by date

Among the 1,317 studies in Head and Neck Neoplasms with a site in United States, this one is the 179th largest by planned enrollment of the 1,073 interventional ones that give a count, is one of 58 that started in 2026, is one of 354 in phase 2, reaches primary completion later than 266 of the 282 other live ones, and was the 1,270th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

187 of the 1,317 studies in Head and Neck Neoplasms with a site in United States are open now. Recruiting first, the newest first:

181 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,317 studies in Head and Neck Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have very good outcomes. Patients' treatment responses depend more on their individual cancer characteristics and personal risk factors than on the specific type of treatment they receive. However, the different treatments used for this cancer can cause significant side effects. Because outcomes are often favorable regardless of treatment type, reducing treatment-related side effects should be a priority when choosing care.

Studies have reported that lowering radiation doses for some patients can reduce side effects while still effectively controlling the cancer.

Patients with this type of head and neck cancer typically receive either surgery or radiation as their first treatment.

For patients who receive surgery first, radiation to the surgical area and nearby neck lymph nodes is often recommended afterward. In these patients, the study will test whether lowering the radiation dose to low-risk lymph nodes on the side of the neck opposite the tumor can reduce side effects while still effectively controlling the cancer (Method A).

For patients who receive radiation as their first treatment, the study will test one or both of two radiation approaches aimed at reducing both short-term and long-term side effects. These approaches include reduced lymph node radiation (Method A, described above) and a tumor dose reduction approach (Method B), which lowers the radiation dose delivered directly to the tumor.

Information such as tumor size, the number of cancerous or suspicious lymph nodes, and risk factors like smoking history will be used to determine which patients may be eligible for reduced lymph node radiation (Method A), reduced tumor radiation (Method B), or both. Patients who may qualify for tumor dose reduction (Method B), either alone or combined with Method A, will need an additional blood test called a circulating tumor DNA (ctDNA) test to determine eligibility.

The ctDNA test measures small amounts of tumor-related DNA in the blood, which are often elevated at the time of diagnosis. Studies have shown that cancer is more likely to return when ctDNA levels remain positive after treatment. This study will evaluate whether ctDNA levels measured before and during treatment can help identify patients who can safely receive lower radiation doses to the tumor (Method B).

Overall, this study aims to safely evaluate two radiation de-escalation approaches in order to lessen short- and long-term side effects while maintaining excellent cancer control.

Read the detailed description

This research study is designed for people with HPV-related head and neck cancer who are being treated with either surgery followed by radiation or radiation as their first treatment. Patients with this type of cancer generally have excellent outcomes, but the treatments can cause significant short- and long-term side effects. Because cancer control is often very good regardless of the specific treatment approach, this study focuses on whether radiation doses can be safely reduced to lessen side effects while still effectively controlling the cancer.

Most patients receive either surgery or radiation as their initial treatment, based on discussions with their medical team. For patients who have surgery first, radiation is often recommended afterward to the surgical area and nearby lymph nodes in the neck. Traditionally, this includes radiation to lymph nodes on both sides of the neck, even the side opposite the tumor. This study will evaluate whether lowering the radiation dose to low-risk lymph nodes on the side opposite the tumor can reduce side effects without compromising cancer control. This approach is called reduced lymph node radiation (Method A).

For patients who receive radiation as their first treatment, radiation is typically given to both the tumor and lymph nodes on both sides of the neck. In these patients, the study will evaluate one or two radiation-reduction strategies. In addition to reduced lymph node radiation (Method A), the study will also examine tumor dose reduction (Method B), which lowers the amount of radiation delivered directly to the tumor itself. Some patients may receive one of these approaches, while others may be eligible for both. Eligibility for these radiation-reduction approaches is based on individual cancer characteristics, such as tumor size, the number of involved lymph nodes, and risk factors like smoking history.

For patients who may qualify for tumor dose reduction (Method B), an additional blood test called a circulating tumor DNA (ctDNA) test is used. This test measures small amounts of tumor DNA in the blood. Studies suggest that patients whose ctDNA levels are negative after treatment are less likely to have their cancer return. In this study, ctDNA testing before treatment and partway through radiation will help identify patients who may be able to safely stop radiation earlier than usual (Method B).

Participants in the study are followed closely as part of their routine cancer care. This includes regular clinic visits, imaging, and physical exams. This also includes research procedures such as questionnaires about symptoms and quality of life. Some participants will also provide additional research-related blood samples to help researchers better understand which factors may predict treatment response and long-term outcomes in the future.

Up to 132 patients will take part in this study at the University of Maryland Medical System. Participation is voluntary, and treatment decisions-such as whether to have surgery or radiation and whether to receive chemotherapy-are made by the patient and their medical team, not determined by the study. However, the study procedures will determine participants' eligibility for and use of one or both of the two radiation reduction approaches.

The goal of this research is to improve future care by identifying safe ways to reduce radiation and treatment-related side effects while maintaining excellent cancer control.

03

Conditions studied

  • Head and Neck Cancer
  • Head and Neck Squamous Cell Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Oropharyngeal Carcinoma
  • Oropharyngeal Squamous Cell Carcinoma (OPSCC)
  • Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
  • Oropharyngeal Squamous Cell Carcinoma
  • Oropharyngeal Squamous Cell Carcinoma (SCC)
  • Oropharyngeal Squamous Cell Carcinoma (OPSCCA)
  • Oropharyngeal Cancer
  • Oropharyngeal Squamous Cell Cancer
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • HPV (Human Papillomavirus)-Associated Carcinoma
  • HPV 16 Positive Oropharyngeal Tumors (OPC)

Keywords

  • Transoral Robotic Surgery (TORS)
  • Head and Neck Cancer
  • Oropharynx Cancer
  • HPV p16 Oropharynx Cancer
  • Proton Therapy
  • Photon Therapy
  • Radiation Therapy
  • ctDNA
  • P16 positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

4.1 Step 1 Registration 4.1.1 Step 1 Inclusion

(Y) 1. Is there pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx or squamous cell carcinoma unknown primary? Note: specimen from cervical lymph nodes with a well-defined primary site documented clinically or radiologically is acceptable; in patients with carcinoma of unknown primary this will be sufficient for pathologic confirmation without a clinically or radiographically defined primary site.

(Y) 2. Is the patient ≥ 18 years of age?

(Y) 3. Did the patient provide study specific prior to study entry, including consent for mandatory submission of tissue for required p16 review?

(Y) 4. Clinical TNM staging criteria by cohort (AJCC 8th edition):

TORS candidate patients must be:

  • cT0-4 and N0, N1, N3

Non-TORS candidate patients must be either:

  • cT1-4 N0, N1, N3
  • cT1-3 N2 with \< 10 pack years

4.1.2 Step 1 Exclusion

(N) 1. Patient who are clinical N2 and have ≥10 pack years smoking history

(N) 2. Patients who are clinical T4N2

(N) 3. Patients with distant (M1)

4.2 Step 2 Registration 4.2.1 Step 2 inclusion

(Y) 1. Does the patient have pathologically (histologically or cytologically) proven P16+ status?

(Y) 2. Does the patient have appropriate imaging (PET/CT preferred, CT neck with IV contrast and CT chest without contrast as recommended alternative to PET/CT) completed within 90 days of enrollment?

(Y) 3. Does the patient have clinical or pathological M0 staging? (Y) 4. Patients who have undergone TORS must have pathological stage pT1-4 N0, N1 or N3. TORS patients found to be clinical N2 post TORS or have contralteral neck dissection and positive nodes will be excluded.

(Y) 5. Is the patient a candidate for bilateral radiation based on evaluation by ENT, Rad Onc, or Med Onc and review at multi-disciplinary tumor board?

(Y) 6. Non-TORS patients who are cT1-3 N0, N1, N2 and have \<10 PY must have completed a ctDNA evaluation prior to Step 2 enrollment.

(Y) 7. Non-TORS patients who are cT1-3 N2 must have a positive ctDNA result prior to Step 2 enrollment.

(Y) 8. Was a general history and physical examination performed by a radiation oncologist, medical oncologist, or head and neck surgeon within 60 days prior to registration?

(Y) 9. Was the patient's Zubrod Performance Status 0-1 within 30 days prior to registration?

(Y) 10. If a woman of or sexually active male, is the patient willing to use effective throughout their participation in the treatment phase of the study and at least 180 days following the last study treatment.

4.2.2 Step 2 Exclusion

(N) 1. Does the patient have cancer considered to be from an oral cavity site (oral tongue, floor mouth, alveolar ridge, buccal or lip), nasopharynx, hypopharynx, or larynx?

(N) 2. Does the patient have distant metastasis?

(N) 3. Does the patient have prior invasive (except non-melanomatous skin cancer and low/intermediate risk prostate cancer) unless disease free for a minimum of 3 years?

(N) 4. Did the patient have prior systemic chemotherapy for the study cancer (prior chemotherapy for a different cancer is allowable)?

(N) 5. Did the patient have prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields?

(N) 6. Did the patient have prior cancer-related surgeries of curative intent of the head and neck excluding superficial removal of cutaneous skin malignancies?

(N) 7. Does the patient have any co-morbid condition or concern that may interfere with follow up per experimental arm?

(N) 8. Does the patient have an active drug or alcohol dependency that in the opinion of the investigator would limit compliance with study requirements?

(N) 9. Is the patient pregnant or nursing (an exception will be made for nursing patients that are not receiving chemotherapy)?

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Selective dose de-escalation of nodAl VolumEs at minimal Risk and primary site Disease

    Radiation: Dose de-escalation to contralateral neck. · Radiation: Dose de-escalation to gross disease to contralateral neck · Radiation: Dose de-escalation to gross disease · Diagnostic Test: Circulating Tumor DNA test (ctDNA test)

Interventions

  • RadiationDose de-escalation to contralateral neck.

    Dose de-escalation of elective treatment volumes including the SAVER-defined volume reduction in the contralateral neck. These patients can be treated in the definitive or adjuvant setting, and have c/pT1-4, N0-1,3 (AJCC 8th ed) disease with a recommendation to treat the contralateral neck. They will undergo treatment with sequential planning of 30Gy to the gross disease and elective neck volumes (using SAVER defined volumes of the contralateral neck) and a subsequent boost to 70Gy for definitive treatment and 50Gy for adjuvant treatment. Chemotherapy will be incorporated per SOC guidelines and based on multi-disciplinary recommendations.

    Also known as: SAVER volume reduction

  • RadiationDose de-escalation to gross disease to contralateral neck

    Dose de-escalation to gross disease for patients treated with definitive chemoRT who meet eligibility for NRG HN 005 (cT1-2N0-2, cT3N0-1 \[AJCC 8th ed\], ≤ 10 Smoking Pack years). Additionally, these patients will require pre-treat positive ctDNA. They will undergo treatment with sequential planning of 30Gy to gross disease and elective neck volumes (using SAVER defined volumes of the contralateral neck). A subsequent boost will be initiated to gross disease. At 4 weeks of treatment, patients will undergo ctDNA analysis. If a patient's ctDNA decreases by ≥95%, final dose will be decreased from SOC dosing for 70Gy to 60Gy (HN-002 dosing). If ctDNA dosing is not resulted by the time patients reach 60Gy, they will continue SOC treatment up to a maximum of 70Gy or until the ctDNA results are available. If there is a ≥95% reduction in ctDNA, treatment will be stopped prior to 70Gy.

  • RadiationDose de-escalation to gross disease

    Dose de-escalation to the gross disease for patients treated with definitive chemoRT who meet eligibility criteria for NRG HN 005 (cT1-2N0-2, cT3N0-1 \[AJCC 8th ed\], ≤ 10 Smoking Pack years). Additionally, these patients will require pre-treatment positive ctDNA levels. At 4 weeks of treatment (after fraction 19 and before fraction 22), patients will undergo ctDNA analysis. If a patient's ctDNA decreases by ≥95%, final dose will be decreased from SOC dosing for 70Gy to 60Gy (HN-002 dosing). If ctDNA dosing is not resulted by the time patients reach 60Gy, they will continue SOC treatment up to a maximum of 70Gy or until the ctDNA results are available. If there is a ≥95% reduction in ctDNA, treatment will be stopped prior to 70Gy.

  • Diagnostic testCirculating Tumor DNA test (ctDNA test)

    Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients who are eligible for dose de-escalation to gross disease, whether they are also eligible for dose de-escalation of contralateral neck or not, will undergo ctDNA evaluation pretreatment, at 4 weeks of treatment, and then at 3, 6, and 12 months post treatment.

06

What researchers measure

Primary outcomes

  1. Freedom From Regional Failures (FFRF)

    The efficacy of dose de-escalation to the elective nodal regions will be evaluated by ensuring a 93% freedom from regional failures (FFRF) at 2 years.

    Time frame: 2 years post treatment

  2. Freedom From Local Recurrence (FFLR)

    The efficacy of de-escalation of dose to gross disease in patients who clear ctDNA will be evaluated by ensuring a 93% Freedom From Local Recurrence (FFLR) at 2 years.

    Time frame: 2 years post treatment

Secondary outcomes

  1. Progression-free Survival (PFS)

    Percent PFS at 2 year post treatment

    Time frame: 2 year post treatment

  2. Overall Survival (OS)

    Time frame: 2 year post treatment

  3. Freedom from Distant Metastases (FFDM)

    Freedom from Distant Metastases (FFDM) at 2 years post last treatment

    Time frame: 2 years post treatment

  4. Number of participants with grade 2/3 xerostomia

    defined by PRO-CTCAE (patient-reported outcome (PRO) measurement system - Common Terminology Criteria for Adverse Events (CTCAE))

    Time frame: [Time Frame: 1-year following completion of treatment]

  5. Patient scores from the questionnaire called The Monroe Dunaway Anderson Dysphagia Inventory (MDADI)

    The M.D. Anderson Dysphagia Inventory is a self-administered questionnaire designed specifically for evaluating the impact of dysphagia on the Quality of Life (QOL) of patients with head and neck cancer. Two scores are obtained: a Global Score and a Composite Score. Global Score ranges from 1 (extremely low functioning) to 5 (high functioning) Composite Score ranges from 20 (extremely low functioning) to 100 (high functioning)

    Time frame: 1-year following completion of treatment

  6. PEG-tube rate

    Percutaneous endoscopic gastrostomy (PEG)-tube rate

    Time frame: 2-year following completion of treatment

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2031, 55 months after the start.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 55 months is close to that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 18, 2026
StartActual
Oct 19, 2026was Sep 2026
Primary completionEst.
May 2031
CompletionEst.
May 2033
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Maryland Proton Treatment Center · Baltimore, United States
  • University of Maryland Greenebaum Cancer Center · Baltimore, United States
  • Central Maryland Radiation Oncology · Columbia, United States
  • Baltimore Washington Medical Center- Tate Cancer Center · Glen Burnie, United States
Nov 6, 2026
Start date
Sep 2026→Oct 19, 2026 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Maryland Proton Treatment Center · Baltimore, United States
    • University of Maryland Greenebaum Cancer Center · Baltimore, United States
    • Central Maryland Radiation Oncology · Columbia, United States
    • Baltimore Washington Medical Center- Tate Cancer Center · Glen Burnie, United States
    Start date Sep 2026→Oct 19, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07418034
Responsible party
Jason Molitoris, MD PhD (Principal Investigator, University of Maryland, Baltimore) — Principal investigator
First posted
Feb 18, 2026
Start date
Oct 19, 2026
Primary completion
May 2031 (estimated)
Completion
May 2033 (estimated)
Last update
Nov 6, 2026

Study contacts

Jason K Molitoris
Contact
jmolitoris@umm.edu
410-328-6080
Kelly Kitzmiller
Contact
kelly.kitzmiller@umm.edu
410-369-5264
Jason K Molitoris
principal investigator · University of Maryland/Maryland Proton Treatment Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion